EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer...
Link Between Obstructive Sleep Apnea And Cancer Growth In Mice
5/18/2011
A new study links the intermittent interruption of breathing that occurs in patients with obstructive sleep apnea (OSA) to enhanced proliferation of melanoma cancer cells and increased tumor growth in mice, according to researchers in Spain. The study also found tumor cells of OSA mouse models tended to contain more dead cells, indicating a more aggressive type of cancer...
Pfizer Inc. announced today that its New Drug Application (NDA) for crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA) and has been filed with the Japanese Ministry of Health, Labour and Welfare (MHLW)...
Potential For A New Breast Cancer Treatment
5/18/2011
Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer. In 20 to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells...
Regular Coffee Reduces Lethal Prostate Cancer Risk
5/18/2011
A man who drinks either caffeinated or decaffeinated coffee regularly has a significantly lower chance of developing a more aggressive from of prostate cancer, researchers from the Harvard School of Public Health revealed in the Journal of the National Cancer Institute...
Improved Survival And Treatment For Chronic Blood Disorders
5/18/2011
New research from the Swedish medical university Karolinska Institutet shows that hydroxyurea, one type of cytotoxic treatment for chronic myeloproliferative blood disorders, does not increase the risk of developing acute leukaemia, as had previously been suspected. Rather, it is the disease itself that mainly increases this risk...
'Blueprint' For Blocking MMP May Unlock New Treatments For Deadly Blood Infection
5/17/2011
Researchers studying the life threatening infectious disease sepsis have discovered how the infection can lead to a fatal inflammatory response through blood vessel cells. The research, which is published in EMBO Molecular Medicine, focuses on blocking crucial Matrix Metalloprotease enzymes (MMP) which activate the response...
Blood Test Claims To Tell You How Long You Have Till You Die
5/17/2011
A new blood test soon to be launched in the United Kingdom claims to be able to tell you how long you are going to live. The £435 ($700) test measures the length of a person's telomeres - the inventor claims this is associated with longevity...
Setting Up Cervical Cancer Screening Programmes In The Developing World
5/17/2011
In this week's PLoS Medicine, Groesbeck Parham from the Centre for Infectious Disease Research in Zambia, and colleagues describe their Cervical Cancer Prevention Program, which has provided services to over 58,000 women over the past five years...
GPs are urged to complete the latest version of Target Ovarian Cancer's award-winning[i] free CPD tool, which has just been updated to include the latest NICE guidance[ii] on new symptoms and best practice for diagnosing ovarian cancer...